CITEseq analysis of non-small-cell lung cancer lesions
Immunotherapy is becoming a mainstay in the treatment of NSCLC. We profiled immune cells of 35 early stage NSCLC lesions using multiscale single cell sequencing, including scRNAseq, CITEseq, and TCRseq.
Provenance — who produced it, who reused it
Linked to 3 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- High-resolution single-cell atlas reveals diversity and plastici... 2022 · 459 cites
2 further papers cite this accession but reuse could not be confirmed.
Deep data QC
53/100 · FStandardized, field-standard QC computed by touching the data — every metric states how it was obtained · evidence: measured
Human bulk-RNA-seq with poor base quality (mean 26.7, scored 0/100) and extreme PCR duplication (79.87%, scored 0/100), making the dataset unsuitable for reliable quantification of gene expression due to high noise and artificial abundance inflation.
The F grade is a transparent weighted average. Each metric below scored from 0–100% against the published bulk-RNA-seq thresholds, weighted by its importance; nothing is hidden or subjective.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0
Scientific quality
Based on hands-on reproduction of the papers that use this dataset. A reproducible paper that stands on this data is positive evidence; a flagged one is a prompt to look closer — never a verdict on the dataset itself without the evidence.